Result for
Tag: vaccines
March 9, 2021
COVID-19 Vaccine Response in Pregnant and Lactating Women a Cohort Study
[Pre-print, not peer-reviewed] The Pfizer-BioNTech and Moderna vaccines elicited similar immune responses among pregnant (n=84) and lactating (n=31) women compared to non-pregnant reproductive-age women (n=16). All vaccine-induced SARS-CoV-2-specific antibody titers were higher compared to titers from a group of pregnant women (n=37) that had SARS-CoV-2 infection 4-12 weeks prior. Vaccine-induced antibodies were detected in all…
Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine, BBV152: Interim Results from a Double-Blind, Randomised, Multicentre, Phase 2 Trial, and 3-Month Follow-up of a Double-Blind, Randomised Phase 1 Trial
Interim results from a double-blind randomized phase 2 trial (n=380) of the Bharat Biotech whole-virion inactivated SARS-CoV-2 vaccine (BBV152) show robust neutralizing titers against wild-type SARS-CoV-2 at day 56 following two doses administered on day 0 and day 28. In a plaque-reduction neutralization test, the 6 µg dose group compared to the 3 µg dose…
Acute Allergic Reactions to MRNA COVID-19 Vaccines
Among employees of Mass General Brigham (MGB), a Boston-based hospital and physicians network, who received their first dose of either the Pfizer-BioNTech or Moderna vaccine (n=64,900), acute allergic reactions of any type were reported by 1,365 employees overall (2.1%) and anaphylaxis was reported by 16 employees (2.5 cases per 10,000 vaccinations).. Among those reporting anaphylaxis,…
March 8, 2021
Comparison of IgG and Neutralizing Antibody Responses after One or Two Doses of COVID-19 MRNA Vaccine in Previously Infected and Uninfected Persons
[Pre-print, not peer-reviewed] A community-based, home-collected, longitudinal serosurvey of 290 participants before and after vaccination with either the Moderna or Pfizer/BioNTech vaccines found that a prior outpatient COVID-19 diagnosis was associated with strong anti-spike RBD IgG and in vitro neutralizing responses after one vaccine dose. Median IgG concentration and percent neutralization after one dose were…
March 4, 2021
Delayed Large Local Reactions to MRNA-1273 Vaccine against SARS-CoV-2
A case series of 12 patients reported delayed large local reactions (skin redness, tenderness and swelling) in response to the Moderna vaccine within 4 to 11 days (median 8 days) after the first dose. In all cases, the reactions appeared near the injection site after complete resolution of the initial local and systemic symptoms associated…
March 3, 2021
Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
[Pre-print, not peer-reviewed] Results from a multicenter, randomized, observer-blinded, placebo-controlled trial in South Africa of the NVX-CoV2373 (Novavax) nanoparticle vaccine indicated that among 2,684 participants who were SARS-CoV-2 seronegative at baseline (94% HIV-negative; 6% people living with HIV), vaccine efficacy was 49.4%, with 15 and 29 predominantly mild to moderate COVID-19 cases in vaccine and…
Early Effectiveness of COVID-19 Vaccination with BNT162b2 MRNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Symptomatic Disease Hospitalisations and Mortality in Older Adults in England
[Pre-print, not peer-reviewed] A study of the real-world effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines in the UK indicated that vaccination with a single dose of either vaccine was associated with a significant reduction in symptomatic COVID-19 cases in older adults, with strong protection against severe disease. Effects of the Pfizer-BioNTech vaccine among adults 80…
March 2, 2021
REACT-2 Round 5 Increasing Prevalence of SARS-CoV-2 Antibodies Demonstrate Impact of the Second Wave and of Vaccine Roll-out in England
[Pre-print, not peer-reviewed] A nationwide cross-sectional study in the England (n=172,000) conducted between January 26 to February 8, 2021 found that the SARS-CoV-2-specific antibody seroprevalence representative of the national population was 14% overall. This figure included seroprevalence due to both immunization and infection. Seroprevalence in unvaccinated people was highest in London and among members of…
Negligible Impact of SARS-CoV-2 Variants on CD4+ and CD8+ T Cell Reactivity in COVID-19 Exposed Donors and Vaccinees
[Pre-print, not peer-reviewed] Bioinformatic analysis suggests that memory T cells generated either by mild SARS-CoV-2 infection (n=11) or mRNA vaccines will not be affected by currently circulating variants. No significant differences were found in the capacity of CD4+ or CD8+ T cells isolated either from convalescent patients following mild disease or vaccinated individuals to recognize…
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
The Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the single-dose Johnson & Johnson COVID-19 vaccine in persons at least 18 years. The February 28, 2021 recommendation was based on a transparent evidence-based review of all available data, primarily informed by the interim analysis of the Phase 3 clinical trials…
Previous page Next page